Back

Inclisiran: a breakthrough in LDL-C reduction for indian ASCVD patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (3) - Risk factors and prevention Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Radha Yalamanchi

Apollo Main Hospitals, Chennai (India)

7 More presentations in this session

Presentation thumbnail
Discussant - Risk factors and prevention
Presentation thumbnail
A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors
Professor L. Rallidis (Athens, GR)
Abstract Video
Presentation thumbnail
Adherence to statin therapy after inclisiran start, insights from the the DAMAGE registry
Associate Professor F. Guerra (Ancona, IT)
Abstract Video
Presentation thumbnail
Short-term impact of e-cigarrette without nicotine in cardiovascular system in comparison to e-cigarette without nicotine and combustile cigarette
Doctor P. Sobieraj (Warsaw, PL)
Abstract
Presentation thumbnail
Disparities in importance physicians place on anti-obesity medications to help prevent cardiovascular comorbidities across the US and Germany
Doctor M. Tan (London, GB)
Abstract Video

Access the full session

Session thumbnail
New perspectives in cardiology (3) - Risk factors and prevention

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Real-world evidence or real-world reality - Is Real world evidence a mirror or magnifier of RCTs?
thumbnail
Congress Session
Late-breaking science on pharmacology
thumbnail
Congress Presentation
VICTORION-Difference study: Inclisiran-based strategy vs standard of care

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources